IPO - Profile


Talis aims to transform diagnostic testing by developing and commercializing innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases and other conditions at the point-of-care. While timely diagnosis of infectious diseases is critically important to enable effective treatment, testing is primarily performed in centralized laboratories, which require samples to be shipped for processing, delaying the return of results by days. Point-of-care testing solves this problem by delivering the timely information necessary for clinical care.

We are developing the Talis One platform, a More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$16.00 13,800,000 Positive High 22.84%

Offering Team

  • Legal counsel
  • Latham & Watkins LLP
  • Auditors
  • Ernst & Young LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 11 Feb, 2021

Offer 12 Feb, 2021

Look Ahead

Lock Up Expiry Aug 12, 2021

IPO Terms

Offer Price $16.00
Offer Size 13M

Market Sentiments

Stock Price